Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
1.
Mol Genet Metab Rep ; 31: 100860, 2022 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-35782617

RESUMEN

Background: Long chain 3-hydroxyacyl-CoA dehydrogenase deficiency (LCHADD) is a rare inherited disease caused by pathogenic variants of HADHA gene. Along with signs common to fatty acid oxidation defects (FAOD), specific retina and heart alterations are observed. Because long-chain fatty acid oxidation is selectively affected, supplementations with short/medium-chain fats represent energetic sources bypassing the enzymatic blockade. Here, we report on an atypical presentation of the disease. Methods: Clinical features were described with medical explorations including ophthalmic and cardiac examination. Biological underlying defects were investigated by measurements of biochemical metabolites and by fluxomic studies of mitochondrial ß-oxidation. Whole exome sequencing and molecular validation of variants confirmed the diagnosis. Results: The patient has developed at nine years an unlabeled maculopathy, and at 28 years, an acute cardiac decompensation without any premise. Blood individual acylcarnitine analysis showed a rise in hydroxylated long-chain fatty acids and fluxomic studies validated enzyme blockade consistent with LCHADD. Genetic analysis revealed the common p.(Glu510Gln) variant in HADHA, in trans with a novel variant c.1108G > A, p.(Gly370Arg) located in the NAD binding domain. Patient pathology was responsive to triheptanoin supplementation. Conclusion: This atypical LCHADD form report should encourage the early assessment of biochemical and genetic testing as a specific management is recommended (combination with fast avoidance, low fat-high carbohydrate diet, medium-even-chain triglycerides or triheptanoin supplementation).

3.
Oxid Med Cell Longev ; 2018: 6986984, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-29765501

RESUMEN

To clarify appropriateness of current claims for health and wellness virtues of argan oil, studies were conducted in inflammatory states. LPS induces inflammation with reduction of PGC1-α signaling and energy metabolism. Argan oil protected the liver against LPS toxicity and interestingly enough preservation of peroxisomal acyl-CoA oxidase type 1 (ACOX1) activity against depression by LPS. This model of LPS-driven toxicity circumvented by argan oil along with a key anti-inflammatory role attributed to ACOX1 has been here transposed to model aging. This view is consistent with known physiological role of ACOX1 in yielding precursors of specialized proresolving mediators (SPM) and with characteristics of aging and related disorders including reduced PGC1-α function and improvement by strategies rising ACOX1 (via hormonal gut FGF19 and nordihydroguaiaretic acid in metabolic syndrome and diabetes conditions) and SPM (neurodegenerative disorders, atherosclerosis, and stroke). Delay of aging to resolve inflammation results from altered production of SPM, SPM improving most aging disorders. The strategic metabolic place of ACOX1, upstream of SPM biosynthesis, along with ability of ACOX1 preservation/induction and SPM to improve aging-related disorders and known association of aging with drop in ACOX1 and SPM, all converge to conclude that ACOX1 represents a previously unsuspected and currently emerging antiaging protein.


Asunto(s)
Envejecimiento/efectos de los fármacos , Antiinflamatorios/uso terapéutico , Lipopolisacáridos/efectos adversos , Oxidorreductasas/uso terapéutico , Aceites de Plantas/uso terapéutico , Acil-CoA Oxidasa , Animales , Antiinflamatorios/farmacología , Modelos Animales de Enfermedad , Humanos , Oxidorreductasas/farmacología , Aceites de Plantas/farmacología
4.
Int J Mol Sci ; 18(10)2017 Oct 19.
Artículo en Inglés | MEDLINE | ID: mdl-29048364

RESUMEN

Sepsis causes severe dysregulation of organ functions, via the development of oxidative stress and inflammation. These pathophysiological mechanisms are mimicked in mice injected with bacterial lipopolysaccharide (LPS). Here, protective properties of argan oil against LPS-induced oxidative stress and inflammation are explored in the murine model. Mice received standard chow, supplemented with argan oil (AO) or olive oil (OO) for 25 days, before septic shock was provoked with a single intraperitoneal injection of LPS, 16 hours prior to animal sacrifice. In addition to a rise in oxidative stress and inflammatory markers, injected LPS also caused hepatotoxicity, accompanied by hyperglycemia, hypercholesterolemia and hyperuremia. These LPS-associated toxic effects were blunted by AO pretreatment, as corroborated by normal plasma parameters and cell stress markers (glutathione: GSH) and antioxidant enzymology (catalase, CAT; superoxide dismutase, SOD and glutathione peroxidase, GPx). Hematoxylin-eosin staining revealed that AO can protect against acute liver injury, maintaining a normal status, which is pointed out by absent or reduced LPS-induced hepatic damage markers (i.e., alanine aminotransferase (ALT) and aspartate transaminase (AST)). Our work also indicated that AO displayed anti-inflammatory activity, due to down-regulations of genes encoding pro-inflammatory cytokines Interleukin-6 (IL-6) and Tumor Necrosis Factor-α (TNF-α) and in up-regulations of the expression of anti-inflammatory genes encoding Interleukin-4 (IL-4) and Interleukin-10 (IL-10). OO provided animals with similar, though less extensive, protective changes. Collectively our work adds compelling evidence to the protective mechanisms of AO against LPS-induced liver injury and hence therapeutic potentialities, in regard to the management of human sepsis. Activations of IL-4/Peroxisome Proliferator-Activated Receptors (IL-4/PPARs) signaling and, under LPS, an anti-inflammatory IL-10/Liver X Receptor (IL-10/LXR) route, obviously indicated the high potency and plasticity of the anti-inflammatory properties of argan oil.


Asunto(s)
Antiinflamatorios/farmacología , Antioxidantes/farmacología , Hepatopatías/tratamiento farmacológico , Hígado/efectos de los fármacos , Aceite de Oliva/farmacología , Estrés Oxidativo , Aceites de Plantas/farmacología , Animales , Antiinflamatorios/administración & dosificación , Antiinflamatorios/uso terapéutico , Antioxidantes/administración & dosificación , Antioxidantes/uso terapéutico , Suplementos Dietéticos , Lipopolisacáridos/toxicidad , Hígado/metabolismo , Hepatopatías/etiología , Hepatopatías/prevención & control , Ratones , Aceite de Oliva/administración & dosificación , Aceite de Oliva/uso terapéutico , Aceites de Plantas/administración & dosificación , Aceites de Plantas/uso terapéutico
5.
PLoS Genet ; 10(11): e1004711, 2014 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-25392908

RESUMEN

Aldolase A deficiency has been reported as a rare cause of hemolytic anemia occasionally associated with myopathy. We identified a deleterious homozygous mutation in the ALDOA gene in 3 siblings with episodic rhabdomyolysis without hemolytic anemia. Myoglobinuria was always triggered by febrile illnesses. We show that the underlying mechanism involves an exacerbation of aldolase A deficiency at high temperatures that affected myoblasts but not erythrocytes. The aldolase A deficiency was rescued by arginine supplementation in vitro but not by glycerol, betaine or benzylhydantoin, three other known chaperones, suggesting that arginine-mediated rescue operated by a mechanism other than protein chaperoning. Lipid droplets accumulated in patient myoblasts relative to control and this was increased by cytokines, and reduced by dexamethasone. Our results expand the clinical spectrum of aldolase A deficiency to isolated temperature-dependent rhabdomyolysis, and suggest that thermolability may be tissue specific. We also propose a treatment for this severe disease.


Asunto(s)
Fiebre/genética , Fructosa-Bifosfato Aldolasa/genética , Enfermedad del Almacenamiento de Glucógeno/genética , Rabdomiólisis/genética , Anemia Hemolítica/genética , Anemia Hemolítica/patología , Arginina/metabolismo , Dexametasona/administración & dosificación , Eritrocitos/patología , Femenino , Fiebre/etiología , Fiebre/patología , Fructosa-Bifosfato Aldolasa/química , Enfermedad del Almacenamiento de Glucógeno/patología , Glucólisis , Humanos , Masculino , Músculo Esquelético/efectos de los fármacos , Músculo Esquelético/patología , Mioblastos/metabolismo , Mioblastos/patología , Linaje , Conformación Proteica , Rabdomiólisis/etiología , Rabdomiólisis/patología
6.
Molecules ; 19(9): 14879-901, 2014 Sep 17.
Artículo en Inglés | MEDLINE | ID: mdl-25232708

RESUMEN

Opuntia ficus-indica, commonly referred to as prickly pear or nopal cactus, is a dicotyledonous angiosperm plant. It belongs to the Cactaceae family and is characterized by its remarkable adaptation to arid and semi-arid climates in tropical and subtropical regions of the globe. In the last decade, compelling evidence for the nutritional and health benefit potential of this cactus has been provided by academic scientists and private companies. Notably, its rich composition in polyphenols, vitamins, polyunsaturated fatty acids and amino acids has been highlighted through the use of a large panel of extraction methods. The identified natural cactus compounds and derivatives were shown to be endowed with biologically relevant activities including anti-inflammatory, antioxidant, hypoglycemic, antimicrobial and neuroprotective properties. The present review is aimed at stressing the major classes of cactus components and their medical interest through emphasis on some of their biological effects, particularly those having the most promising expected health benefit and therapeutic impacts.


Asunto(s)
Opuntia/química , Extractos Vegetales/farmacología , Animales , Antiinflamatorios/farmacología , Antiinflamatorios/uso terapéutico , Antioxidantes/farmacología , Antioxidantes/uso terapéutico , Ensayos de Selección de Medicamentos Antitumorales , Humanos , Extractos Vegetales/uso terapéutico , Polifenoles/farmacología , Polifenoles/uso terapéutico
7.
Biochem Biophys Res Commun ; 446(3): 798-804, 2014 Apr 11.
Artículo en Inglés | MEDLINE | ID: mdl-24582563

RESUMEN

The objective of this study was to evaluate the biological activities of the major phytosterols present in argan oil (AO) and in cactus seed oil (CSO) in BV2 microglial cells. Accordingly, we first determined the sterol composition of AO and CSO, showing the presence of Schottenol and Spinasterol as major sterols in AO. While in CSO, in addition to these two sterols, we found mainly another sterol, the Sitosterol. The chemical synthesis of Schottenol and Spinasterol was performed. Our results showed that these two phytosterols, as well as sterol extracts from AO or CSO, are not toxic to microglial BV2 cells. However, treatments by these phytosterols impact the mitochondrial membrane potential. Furthermore, both Schottenol and Spinasterol can modulate the gene expression of two nuclear receptors, liver X receptor (LXR)-α and LXRß, their target genes ABCA1 and ABCG1. Nonetheless, only Schottenol exhibited a differential activation vis-à-vis the nuclear receptor LXRß. Thus Schottenol and Spinasterol can be considered as new LXR agonists, which may play protective roles by the modulation of cholesterol metabolism.


Asunto(s)
Microglía/efectos de los fármacos , Receptores Nucleares Huérfanos/agonistas , Aceites de Plantas/química , Sitoesteroles/farmacología , Estigmasterol/análogos & derivados , Transportador 1 de Casete de Unión a ATP/genética , Transportador de Casetes de Unión a ATP, Subfamilia G, Miembro 1 , Transportadoras de Casetes de Unión a ATP/genética , Animales , Línea Celular/efectos de los fármacos , Regulación de la Expresión Génica/efectos de los fármacos , Lipoproteínas/genética , Receptores X del Hígado , Potencial de la Membrana Mitocondrial/efectos de los fármacos , Ratones , Microglía/citología , Opuntia/química , Receptores Nucleares Huérfanos/genética , Semillas/química , Esteroles/análisis , Estigmasterol/síntesis química , Estigmasterol/farmacología
8.
Artículo en Inglés | MEDLINE | ID: mdl-22749692

RESUMEN

The anticonvulsant and mood stabilizer drug carbamazepine (CBZ) was evaluated for anti-seizure activity after drug pretreatment of young weaning mice given various oil-based diets. These diets had various mono-(MUFA) and poly-(PUFA) unsaturated fatty acid contents, were associated or not with magnesium deprivation, and were given over the entire experimental period (34 days). The diets included a commercial and three purified synthetic diets (n-6 PUFA, n-3 PUFA and MUFA-based chows containing 5% corn/sunflower oils 1:3, 5% rapeseed oil and 5% high oleic acid sunflower oil/sunflower oil 7:3, respectively). A 10-days CBZ treatment (50 mg/kg/day fragmented in two daily intraperitoneal injections of 25 mg/kg) was given 20 days after initiating diet administration and evaluations of mice was performed 4 days after arrest of CBZ in various seizure tests. In these conditions, CBZ pretreatment still exhibited anticonvulsant protection especially in magnesium-deficient animals. Ethosuximide (ESM)-like profiles under MUFA and n-3 PUFA diets and unusual GABA(A)ergic profile under n-6 PUFA diet in magnesium-deficiency dependent audiogenic seizures (MDDAS) test as well as protection against NMDA-induced seizures in all lipid (n-3 PUFA>MUFA and n-6 PUFA) diet conditions were observed in CBZ-pretreated mice. By highlighting ESM-like and anti-NMDA mechanisms previously induced by an n-3 PUFA diet, present CBZ anticonvulsant properties suggest brain protective targets common to CBZ and n-3 PUFAs.


Asunto(s)
Anticonvulsivantes/administración & dosificación , Encéfalo/efectos de los fármacos , Carbamazepina/administración & dosificación , Ácidos Grasos Omega-3/administración & dosificación , Ácidos Grasos Omega-6/administración & dosificación , Magnesio/administración & dosificación , Animales , Anticonvulsivantes/farmacología , Ácido Araquidónico/metabolismo , Encéfalo/metabolismo , Carbamazepina/farmacología , Dieta , Esquema de Medicación , Epilepsia Refleja/etiología , Epilepsia Refleja/prevención & control , Femenino , Deficiencia de Magnesio/complicaciones , Ratones , N-Metilaspartato , Fenobarbital/administración & dosificación , Fenobarbital/farmacología , Fenitoína/administración & dosificación , Fenitoína/farmacología , Convulsiones/etiología , Convulsiones/prevención & control , Transducción de Señal
9.
Artículo en Inglés | MEDLINE | ID: mdl-21664114

RESUMEN

Diets given for 30 days with various mono-(MUFA) and poly-(PUFA) unsaturated fatty acid contents were evaluated for brain protection in magnesium-deficient mice: a commercial and three synthetic diets (n-6PUFA, n-3PUFA and MUFA-based chows enriched with 5% corn/sunflower oils 1:3, with 5% rapeseed oil and with 5% high oleic acid sunflower oil/sunflower oil 7:3, respectively). Unlike magnesium deprivation, they induced significant differences in brain and erythrocyte membrane phospholipid fatty acid compositions. n-3PUFA but not other diets protected magnesium-deficient mice against hyperactivity and moderately towards maximal electroshock- and NMDA-induced seizures. This diet also inhibited audiogenic seizures by 50%, preventing animal deaths. Because, like n-6PUFA diet, matched control MUFA diet failed to induce brain protections, alpha-linolenate (ALA) rather than reduced n-6 PUFA diet content is concluded to cause n-3PUFA neuroprotection. Present in vivo data also corroborate literature in vitro inhibition of T type calcium channels by n-3 PUFA, adding basis to ALA supplementation in human anti-epileptic/neuroprotective strategies.


Asunto(s)
Encéfalo/efectos de los fármacos , Grasas Insaturadas en la Dieta/administración & dosificación , Membrana Eritrocítica/efectos de los fármacos , Deficiencia de Magnesio/tratamiento farmacológico , Aceites de Plantas/administración & dosificación , Animales , Encéfalo/citología , Encéfalo/metabolismo , Grasas Insaturadas en la Dieta/farmacología , Membrana Eritrocítica/metabolismo , Ácidos Grasos Monoinsaturados/administración & dosificación , Ácidos Grasos Monoinsaturados/farmacología , Ácidos Grasos Omega-3/administración & dosificación , Ácidos Grasos Omega-3/farmacología , Femenino , Humanos , Deficiencia de Magnesio/metabolismo , Ratones , Modelos Animales , Fármacos Neuroprotectores/administración & dosificación , Fármacos Neuroprotectores/farmacología , Fosfolípidos/metabolismo , Aceites de Plantas/farmacología , Aceite de Brassica napus
10.
Br J Nutr ; 101(3): 317-21, 2009 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-21129231

RESUMEN

Magnesium deficiency may be induced by a diet impoverished in magnesium. This nutritional deficit promotes chronic inflammatory and oxidative stresses, hyperexcitability and, in mice, susceptibility to audiogenic seizures. Potentiation by low-magnesium concentrations of the opening of N-methyl-D-aspartate (NMDA) receptor/calcium channel in in vitro and ex vivo studies, and responsiveness to magnesium of in vivo brain injury states are now well established. By contrast, little or no specific attention has been, however, paid to the in vivo NMDA receptor function/excitability in magnesium deficiency. The present work reports for the first time that, in mice undergoing chronic nutritional deprivation in magnesium (35 v. 930 parts per million for 27 d in OF1 mice), NMDA-induced seizure threshold is significantly decreased (38 % of normal values). The attenuation in the drop of NMDA seizure threshold (percentage of reversal) was 58 and 20 % upon acute intraperitoneal administrations of magnesium chloride hexahydrate (28 mg magnesium/kg) and the antioxidant ebselen (20 mg/kg), respectively. In nutritionally magnesium-deprived animals, audiogenic seizures are completely prevented by these compound doses. Taken as a whole, our data emphasise that chronic magnesium deprivation in mice is a nutritional in vivo model for a lowered NMDA receptor activation threshold. This nutritional model responds remarkably to acute magnesium supply and moderately to acute antioxidant administration.


Asunto(s)
Antioxidantes/farmacología , Azoles/farmacología , Deficiencia de Magnesio/complicaciones , Magnesio/farmacología , N-Metilaspartato/toxicidad , Compuestos de Organoselenio/farmacología , Convulsiones/inducido químicamente , Estimulación Acústica/efectos adversos , Animales , Antioxidantes/administración & dosificación , Azoles/administración & dosificación , Relación Dosis-Respuesta a Droga , Isoindoles , Magnesio/administración & dosificación , Deficiencia de Magnesio/tratamiento farmacológico , Ratones , Compuestos de Organoselenio/administración & dosificación , Convulsiones/etiología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA